Xeris Pharmaceuticals Awarded Phase I-II NIH SBIR Fast Track Grant to Advance a Stable, Non-Aqueous Diazepam, Subcutaneous Injection for Treatment of Acute Repetitive Seizures in Patients with Epilepsy
October 01, 2015 10:15 ET
|
Xeris Pharmaceuticals, Inc.
Austin, Texas, Oct. 01, 2015 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), an Austin-based, emerging biopharmaceutical company developing patient-friendly injectable treatments, was...
![Coriell Institute for Medical Research Logo](/news-release/logo/332486/0/332486.jpg?lastModified=12%2F10%2F2016%2001%3A15%3A15&size=2)
Coriell Institute Wins $6.5M Award from NIH; Advances Studies on Centenarians
June 10, 2015 12:03 ET
|
Coriell Institute for Medical Research
CAMDEN, N.J., June 10, 2015 (GLOBE NEWSWIRE) -- The Coriell Institute for Medical Research has won a five-year, $6.5M award from the National Institutes of Health (NIH) to advance research on aging,...
![Three Wire Systems](/news-release/logo/291490/0/291490.jpg?lastModified=12%2F09%2F2016%2023%3A14%3A47&size=2)
Three Wire Systems Awarded CIO-CS Contract
April 21, 2015 13:05 ET
|
Three Wire Systems, LLC
Falls Church, VA, April 21, 2015 (GLOBE NEWSWIRE) -- The National Institutes of Health (NIH)
announced today that Three Wire Systems, LLC was awarded one of its
Chief Information Officer - Commodities...
Xeris Pharmaceuticals Awarded Phase I-II NIH SBIR Fast Track Grant to Advance Stable, Non-Aqueous Glucagon for Treatment of Congenital Hyperinsulinism, an Orphan Disease
April 14, 2015 14:00 ET
|
Xeris Pharmaceuticals, Inc.
Austin, Texas, April 14, 2015 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), an Austin-based, emerging biopharmaceutical company developing patient-friendly injectable treatments for...
![Coriell Institute for Medical Research - Biobank](http://www.globenewswire.com/en/Attachment/LogoDisplay/332487?filename=332487.jpg&size=2)
NIH Awards Coriell Institute $14M Grant to Collect, Characterize, and Distribute Cells and DNA from Hundreds of Human Genetic Diseases
March 16, 2015 10:17 ET
|
Coriell Institute for Medical Research
CAMDEN, N.J., March 16, 2015 (GLOBE NEWSWIRE) -- Coriell Institute for Medical Research, home to the world's most diverse collection of samples from human genetic diseases and a leading center for...
![DrChanZebraFishLab](http://www.globenewswire.com/en/Attachment/LogoDisplay/313184?filename=313184.jpg&size=2)
Hampton University Receives NIH Grant to Study Treatment for Infectious Diseases
October 07, 2014 10:46 ET
|
Hampton University
HAMPTON, Va., Oct. 7, 2014 (GLOBE NEWSWIRE) -- The Hampton University Department of Biological Sciences has been awarded a $900,000 grant from the National Institute of Allergy and Infectious Diseases...
Mesoblast Unveils Path to Bring Its Key Products to Market
August 25, 2014 20:27 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 25, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported 2014 financial results and unveiled its...
National Institutes of Health and Mesoblast Enter Into Agreement for 120-Patient Trial In End-Stage Heart Failure
August 06, 2014 20:57 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced the signing of an agreement with the United...
National Press Coverage for Medical Marijuana, Inc. -- Portfolio Company Kannalife Sciences Awarded NIH License to Develop Target Drugs to Treat Concussion Syndrome CTE Using Marijuana
August 05, 2014 14:45 ET
|
Medical Marijuana Inc
SAN DIEGO, Aug. 5, 2014 (GLOBE NEWSWIRE) -- Medical Marijuana, Inc. (OTC Pink: MJNA) is pleased to announce that one of its investment portfolio companies, KannaLife Sciences, Inc. ("KannaLife"), a...
Improved Outcomes Using Mesoblast Cells in End-Stage Heart Failure
June 24, 2014 21:19 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, June 24, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that trial results evaluating a low dose...